Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-03

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

NCT00407563

Epithelial Ovarian Cancer Primary Peritoneal Carcinoma

COMPLETED PHASE2

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

NCT07146919

Endometrial Carcinoma Ovarian Cancer Cervix Cancer

NOT_YET_RECRUITING PHASE1/PHASE2

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

NCT06304922

Ovarian Cancer

NOT_YET_RECRUITING

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT01837251

Recurrent Platinum-sensitive Ovarian Cancer

COMPLETED PHASE3

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

NCT01802749

Recurrent Ovarian Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
* Male or female (aged ≥18 years old)
* Performance Status (PS) between 0 and 2
* Expected life\> 3 months
* Ability to answer a self-questionnaire
* Obtaining the non-opposition of patient participation

Exclusion Criteria

* Pregnant or lactating woman
* Rapid evolution of neoplastic pathology
* Major cognitive disorders that do not allow filling of the self-questionnaire
* Impossibility to submit to medical monitoring for social, psychological or geographical reasons
* Patients under guardianship or curatorship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No